Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends
С. О. Бачурин, Elena Bovina, A. A. Ustyugov
Medicinal Research Reviews (2017) Vol. 37, Iss. 5, pp. 1186-1225
Closed Access | Times Cited: 279

Showing 1-25 of 279 citing articles:

Current state of Alzheimer’s fluid biomarkers
José Luís Molinuevo, Scott Ayton, Richard Batrla, et al.
Acta Neuropathologica (2018) Vol. 136, Iss. 6, pp. 821-853
Open Access | Times Cited: 445
BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease
Nour M. Moussa‐Pacha, Shifaa M. Abdin, Hany A. Omar, et al.
Medicinal Research Reviews (2019) Vol. 40, Iss. 1, pp. 339-384
Open Access | Times Cited: 245
Advances in developing novel therapeutic strategies for Alzheimer’s disease
Jiqing Cao, Jianwei Hou, Jing Ping, et al.
Molecular Neurodegeneration (2018) Vol. 13, Iss. 1
Open Access | Times Cited: 237
Vascular Dysfunction in Alzheimer’s Disease: A Prelude to the Pathological Process or a Consequence of It?
Karan Govindpani, Laura G McNamara, Nicholas R Smith, et al.
Journal of Clinical Medicine (2019) Vol. 8, Iss. 5, pp. 651-651
Open Access | Times Cited: 210
Blood-brain barrier–penetrating siRNA nanomedicine for Alzheimer’s disease therapy
Yutong Zhou, Feiyan Zhu, Yang Liu, et al.
Science Advances (2020) Vol. 6, Iss. 41
Open Access | Times Cited: 208
A Perspective on Multi-target Drugs for Alzheimer’s Disease
Ondřej Benek, Jan Korábečný, Ondřej Soukup
Trends in Pharmacological Sciences (2020) Vol. 41, Iss. 7, pp. 434-445
Closed Access | Times Cited: 204
Functional supramolecular systems: design and applications
И. С. Антипин, М. В. Алфимов, V. V. Arslanov, et al.
Russian Chemical Reviews (2021) Vol. 90, Iss. 8, pp. 895-1107
Closed Access | Times Cited: 119
Blood-Based Biomarkers for Alzheimer’s Disease Diagnosis and Progression: An Overview
Angelica Varesi, Adelaide Carrara, Vitor Gomes Pires, et al.
Cells (2022) Vol. 11, Iss. 8, pp. 1367-1367
Open Access | Times Cited: 76
A one-two punch targeting reactive oxygen species and fibril for rescuing Alzheimer’s disease
Jiefei Wang, Ping Shangguan, Xiaoyu Chen, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 29
Mannose-Integrated Nanoparticle Hitchhike Glucose Transporter 1 Recycling to Overcome Various Barriers of Oral Delivery for Alzheimer’s Disease Therapy
Ting Lei, Zixiao Yang, Chaoqing Jiang, et al.
ACS Nano (2024) Vol. 18, Iss. 4, pp. 3234-3250
Closed Access | Times Cited: 25
Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
Judite R.M. Coimbra, Daniela F. F. Marques, Salete J. Baptista, et al.
Frontiers in Chemistry (2018) Vol. 6
Open Access | Times Cited: 152
Multifactorial Hypothesis and Multi-Targets for Alzheimer’s Disease
Cheng‐Xin Gong, Fei Liu, Khalid Iqbal
Journal of Alzheimer s Disease (2018) Vol. 64, Iss. s1, pp. S107-S117
Closed Access | Times Cited: 145
FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease
Petr Novák, Reinhold Schmidt, Eva Kontseková, et al.
Alzheimer s Research & Therapy (2018) Vol. 10, Iss. 1
Open Access | Times Cited: 119
Activation of PKA/SIRT1 signaling pathway by photobiomodulation therapy reduces Aβ levels in Alzheimer's disease models
Zhan Zhang, Qi Shen, Xiaolei Wu, et al.
Aging Cell (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 114
β-Amyloid and the Pathomechanisms of Alzheimer’s Disease: A Comprehensive View
Botond Penke, Ferenc Bogár, Lívia Fülöp
Molecules (2017) Vol. 22, Iss. 10, pp. 1692-1692
Open Access | Times Cited: 101
Future Therapeutic Perspectives into the Alzheimer’s Disease Targeting the Oxidative Stress Hypothesis
Jéssika Poliana Teixeira, Alexandre A. de Castro, Flávia V. Soares, et al.
Molecules (2019) Vol. 24, Iss. 23, pp. 4410-4410
Open Access | Times Cited: 95
Advance of sporadic Alzheimer's disease animal models
Lili Zhang, Chen Chen, Marvin SH Mak, et al.
Medicinal Research Reviews (2019) Vol. 40, Iss. 1, pp. 431-458
Closed Access | Times Cited: 92
The role of repetitive transcranial magnetic stimulation (rTMS) in the treatment of cognitive impairment in patients with Alzheimer's disease: A systematic review and meta-analysis
Yan Lin, Wenjing Jiang, Peiyan Shan, et al.
Journal of the Neurological Sciences (2019) Vol. 398, pp. 184-191
Closed Access | Times Cited: 89
FA-97, a New Synthetic Caffeic Acid Phenethyl Ester Derivative, Protects against Oxidative Stress-Mediated Neuronal Cell Apoptosis and Scopolamine-Induced Cognitive Impairment by Activating Nrf2/HO-1 Signaling
Ting Wan, Zihao Wang, Yi Luo, et al.
Oxidative Medicine and Cellular Longevity (2019) Vol. 2019, pp. 1-21
Open Access | Times Cited: 85
Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer’s Disease: Are Irreversible Inhibitors the Future?
Donald E. Moss
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 10, pp. 3438-3438
Open Access | Times Cited: 81
The Role of Selected Bioactive Compounds in the Prevention of Alzheimer’s Disease
Wojciech Grodzicki, Katarzyna Dziendzikowska
Antioxidants (2020) Vol. 9, Iss. 3, pp. 229-229
Open Access | Times Cited: 80
Copper-Targeting Approaches in Alzheimer’s Disease: How To Improve the Fallouts Obtained from in Vitro Studies
Charlène Esmieu, Djamila Guettas, Amandine Conte‐Daban, et al.
Inorganic Chemistry (2019) Vol. 58, Iss. 20, pp. 13509-13527
Open Access | Times Cited: 76
Investigation of the Molecular Role of Brain-Derived Neurotrophic Factor in Alzheimer’s Disease
Pragya Girotra, Tapan Behl, Aayush Sehgal, et al.
Journal of Molecular Neuroscience (2021) Vol. 72, Iss. 2, pp. 173-186
Closed Access | Times Cited: 60
Microenvironment modulating nanogels by Shiitake-derived lentinan and a reactive oxygen species scavenging conjugated polymer for the treatment of Alzheimer’s disease
Yanru Xin, Fang Fang, Qiang Yue, et al.
Nano Today (2024) Vol. 55, pp. 102178-102178
Closed Access | Times Cited: 13
Fused thiophene as a privileged scaffold: A review on anti-Alzheimer's disease potentials via targeting cholinesterases, monoamine oxidases, glycogen synthase kinase-3, and Aβ aggregation
Asmaa E. Kassab, Ehab M. Gedawy, Alaa S. Sayed
International Journal of Biological Macromolecules (2024) Vol. 265, pp. 131018-131018
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top